Market Research Life Sciences Market Research Medical Devices Market Research Stents Market Research

Drug Eluting Stents (DES) Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

Best Price Guarantee Length Publisher Published Date SKU
from $4,000 140 Pages GlobalData December, 2023 GBDT18399838
Best Price Guarantee
Price from $4,000
Length 140 Pages
Publisher GlobalData
Published Date December, 2023
SKU GBDT18399838

Drug Eluting Stents (DES) Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies


Summary

GlobalData's Medical Devices sector report, “Drug Eluting Stents (DES) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Drug Eluting Stents (DES) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Drug eluting stents (DES) release drugs locally and can be coated with a polymeric material. The stent releases an antiproliferative or immunosuppressive drug over time, leaving behind the metallic stent in the artery.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Drug Eluting Stents (DES) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Drug Eluting Stents (DES) Overview
4 Products under Development
4.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
4.2 Drug Eluting Stents (DES) - Pipeline Products by Territory
4.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
4.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
4.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials
5 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies
5.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
5.2 Drug Eluting Stents (DES) – Companies Pipeline Products by Stage of Development
6 Drug Eluting Stents (DES) Companies and Product Overview
6.1 Abbott Vascular Inc Company Overview
6.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
6.2 Adcomp Technologies Inc. Company Overview
6.2.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
6.3 Advanced Bifurcation Systems Inc Company Overview
6.3.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
6.4 Aeon Bioscience Company Overview
6.4.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
6.5 B. Braun Melsungen AG Company Overview
6.5.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
6.6 Biosensors International Group Ltd Company Overview
6.6.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.7 Biotronik AG Company Overview
6.7.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
6.8 Biotronik SE & Co KG Company Overview
6.8.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
6.9 Boston Scientific Corp Company Overview
6.9.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
6.1 Cardionovum GmbH Company Overview
6.10.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
6.11 Cardiorev Pte Ltd (Inactive) Company Overview
6.11.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
6.12 Columbia University Company Overview
6.12.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
6.13 Concept Medical Inc Company Overview
6.13.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
6.14 Cordis Corp Company Overview
6.14.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
6.15 DISA Vascular (Pty) Ltd Company Overview
6.15.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.16 Elixir Medical Corp Company Overview
6.16.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
6.17 Endomimetics LLC Company Overview
6.17.1 Endomimetics LLC Pipeline Products & Ongoing Clinical Trials Overview
6.18 Envision Scientific Pvt Ltd Company Overview
6.18.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.19 I.B.S. S.p.A. Company Overview
6.19.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
6.2 InspireMD Inc Company Overview
6.20.1 InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
6.21 JW Medical Systems Ltd Company Overview
6.21.1 JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.22 Kaneka Corp Company Overview
6.22.1 Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
6.23 MangoGen Pharma Inc Company Overview
6.23.1 MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
6.24 Medinol Ltd Company Overview
6.24.1 Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.25 Medlogics Device Corp (Inactive) Company Overview
6.25.1 Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
6.26 Medtronic Plc Company Overview
6.26.1 Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
6.27 MicroPort Scientific Corp Company Overview
6.27.1 MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
6.28 MIV Therapeutics Inc Company Overview
6.28.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
6.29 Northwestern University Company Overview
6.29.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
6.3 NuVascular Technologies Inc Company Overview
6.30.1 NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
6.31 Relisys Medical Devices Ltd Company Overview
6.31.1 Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.32 REVA Medical Inc Company Overview
6.32.1 REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
6.33 Shandong Rientech Medical Tech Co Ltd Company Overview
6.33.1 Shandong Rientech Medical Tech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.34 Shanghai BIOMAGIC Medical Device Co Ltd Company Overview
6.34.1 Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.35 Shanghai MicroPort Medical Group Co Ltd Company Overview
6.35.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
6.36 Sino Medical Sciences Technology Inc Company Overview
6.36.1 Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
6.37 Stentys SA Company Overview
6.37.1 Stentys SA Pipeline Products & Ongoing Clinical Trials Overview
6.38 Svelte Medical Systems Inc Company Overview
6.38.1 Svelte Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
6.39 Terumo Corp Company Overview
6.39.1 Terumo Corp Pipeline Products & Ongoing Clinical Trials Overview
6.4 Terumo Interventional Systems Company Overview
6.40.1 Terumo Interventional Systems Pipeline Products & Ongoing Clinical Trials Overview
6.41 TissueGen Inc Company Overview
6.41.1 TissueGen Inc Pipeline Products & Ongoing Clinical Trials Overview
6.42 Translumina Therapeutics LLP Company Overview
6.42.1 Translumina Therapeutics LLP Pipeline Products & Ongoing Clinical Trials Overview
6.43 University of Strathclyde Company Overview
6.43.1 University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
6.44 VasoTech Inc. Company Overview
6.44.1 VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
7 Drug Eluting Stents (DES)- Recent Developments
7.1 Nov 10, 2023: Microport Appointment of Director
7.2 Oct 26, 2023: Five-Year Superiority Proven for Orsiro Des Over Xience Des in Stemi Patients
7.3 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
7.4 Oct 25, 2023: TCT 2023: Six-Month Clinical Data from DESyne BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
7.5 Oct 24, 2023: Medinol Receives FDA Approval for Next Generation Elunir-Perl Drug-Eluting Coronary Stent System
7.6 Oct 23, 2023: Advanced Bifurcation Systems Receives FDA Breakthrough Device Designation
7.7 Oct 18, 2023: Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
7.8 Oct 05, 2023: Elixir Medical to Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023
7.9 Oct 04, 2023: Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
7.1 Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business
7.11 Sep 21, 2023: Microport Scientific Corp. Announces 2023 Interim Report
7.12 Sep 11, 2023: Multiple MicroPort Business Groups Make an Appearance at SOLACI-SBHCI 2023
7.13 Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair
7.14 Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
7.15 Jul 19, 2023: Boston Scientific Lays off 52 Amid California Facility Closure
7.16 Jul 13, 2023: Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
7.17 Jul 11, 2023: Late-Breaking Study Data: BIOTRONIK’s Orsiro DES Outperforms Other Ultrathin Strut Drug-Eluting Stent
7.18 Jul 11, 2023: Microport Scientific Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023
7.19 Jun 12, 2023: Abbott Names Philip Boudreau CFO effective Sept. 1
7.2 Jun 02, 2023: MicroPort Group's Multiple Business Units Participate in the European Cardiovascular Intervention Conference
7.21 May 30, 2023: Medinol partners with CoSo Health to Launch the EluNIR Drug-Eluting Stent in the U.S.
7.22 May 15, 2023: Terumo announces consolidated financial results for the fiscal year ended March 31, 2023
7.23 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023
7.24 Apr 26, 2023: MicroPort announces annual results for 2022
7.25 Apr 23, 2023: MicroPort announces release of TARGET-FIRST study design for the Firehawk Coronary Stent
7.26 Apr 12, 2023: Medtronic has a layoff in California
7.27 Mar 16, 2023: Medtronic joins in $25M funding round for home monitoring company
7.28 Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
7.29 Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023
7.3 Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022
7.31 Jan 20, 2023: MicroPort joins Singapore LIVE 2023
7.32 Jan 04, 2023: Firehawk Liberty Rapamycin target eluting coronary stent system approved for marketing in Russia
7.33 Dec 08, 2022: Ultimaster Drug Eluting Stent family (Terumo) first stent to receive the mention 1-month DAPT in the reimbursement conditions in France
8 Appendix
8.1 Methodology
8.2 About GlobalData
8.3 Contact Us
8.4 Disclaimer
2.1 List of Tables
Table 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
Table 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
Table 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
Table 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
Table 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
Table 6: Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
Table 7: Drug Eluting Stents (DES) – Companies Pipeline Products by Stage of Development
Table 8: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Xience Bioprime - Product Status
Table 10: Xience Bioprime - Product Description
Table 11: Xience Max - Product Status
Table 12: Xience Max - Product Description
Table 13: Xience SBA Everolimus Eluting Coronary Stent System - Product Status
Table 14: Xience SBA Everolimus Eluting Coronary Stent System - Product Description
Table 15: XIENCE Thinman DES - Product Status
Table 16: XIENCE Thinman DES - Product Description
Table 17: ZoMaxx Drug Eluting Coronary Stent System - Product Status
Table 18: ZoMaxx Drug Eluting Coronary Stent System - Product Description
Table 19: Abbott Vascular Inc - Ongoing Clinical Trials Overview
Table 20: Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
Table 21: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective, Multi-center, Single-blinded, Randomized Trial of the Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-II
Table 22: Xience SBA Everolimus Eluting Coronary Stent System - Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
Table 23: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 24: Dual Drug Eluting Stent - Product Status
Table 25: Dual Drug Eluting Stent - Product Description
Table 26: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 27: ABS Stenting System - Drug Eluting Stent - Product Status
Table 28: ABS Stenting System - Drug Eluting Stent - Product Description
Table 29: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 30: Drug Eluting Stent - Product Status(Aeon Bioscience)
Table 31: Drug Eluting Stent - Product Description(Aeon Bioscience)
Table 32: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
Table 33: Coroflex DEBlue - Product Status
Table 34: Coroflex DEBlue - Product Description
Table 35: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 36: BioFreedom Ultra - Product Status
Table 37: BioFreedom Ultra - Product Description
Table 38: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
Table 39: BioFreedom Ultra - A Pilot Study Registry of the BioFreedom BA9 Ultra Drug-Coated Coronary Stent for Patients With ST Elevation Myocardial Infarct (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
Table 40: BioFreedom Ultra - A Post-Market Registry of the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System
Table 41: BioFreedom Ultra - A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of Additional Sizes of the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System
Table 42: BioFreedom Ultra - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
Table 43: BioFreedom Ultra - BioFreedom Ultra Stent in Hong Kong All Comers Registry
Table 44: BioFreedom Ultra - Comparison of Polymer-free Cobalt-Chromium Thin Drug-coated Stents with Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy with Conventional 12-Month Dual Antiplatelet Therapy
Table 45: BioFreedom Ultra - Evaluation of Effectiveness and Safety of Biofreedom Family Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Table 46: BioFreedom Ultra - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 47: BioFreedom Ultra - P2Y12 Inhibitor-based Single Antiplatelet Therapy Versus Conventional Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With BioFreedom Ultra Drug-coated Stent for Unprotected Left Main Coronary Artery Disease (ULTRA-LM)
Table 48: BioFreedom Ultra - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
Table 49: BioFreedom Ultra - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
Table 50: Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
Table 51: Coronary Stent System - Product Status
Table 52: Coronary Stent System - Product Description
Table 53: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
Table 54: ProGenic Pimecrolimus-eluting Coronary Stent System - Product Status
Table 55: ProGenic Pimecrolimus-eluting Coronary Stent System - Product Description
Table 56: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 57: JACTAX Drug Eluting Stent - Product Status
Table 58: JACTAX Drug Eluting Stent - Product Description
Table 59: SYNERGY 48 Stent - Product Status
Table 60: SYNERGY 48 Stent - Product Description
Table 61: SYNERGY XD Stent - Product Status
Table 62: SYNERGY XD Stent - Product Description
Table 63: TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Status
Table 64: TAXUS Petal Bifurcation Paclitaxel-Eluting Stent System - Product Description
Table 65: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 66: SYNERGY XD Stent - Evaluation of Effectiveness and Safety of Synergy™ XD Stent and Synergy Megatron™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Table 67: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 68: DEBLIMUS - Product Status
Table 69: DEBLIMUS - Product Description
Table 70: PROTECT - Product Status
Table 71: PROTECT - Product Description
Table 72: ReNATURAL (M) - Product Status
Table 73: ReNATURAL (M) - Product Description
Table 74: ReNATURAL (P) - Product Status
Table 75: ReNATURAL (P) - Product Description
Table 76: Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Peptide-Eluting Coronary Stent - Product Status
Table 78: Peptide-Eluting Coronary Stent - Product Description
Table 79: Columbia University Pipeline Products & Ongoing Clinical Trials Overview
Table 80: C3 Exoenzyme Coated Stent - Product Status
Table 81: C3 Exoenzyme Coated Stent - Product Description
Table 82: Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 83: Abluminus DES+ - Product Status
Table 84: Abluminus DES+ - Product Description
Table 85: Concept Medical Inc - Ongoing Clinical Trials Overview
Table 86: Abluminus DES+ - A Multicenter, Prospective, Study to Evaluate the Safety and Effcacy of the Abluminus DES+ in an All-Comers Population
Table 87: Abluminus DES+ - A Post Market Registry of Abluminus Sirolimus Eluting Coronary Stent System for Percutaneous Intervention in Patients with Diabetes Mellitus
Table 88: Abluminus DES+ - ABILITY Diabetes Global
Table 89: Abluminus DES+ - ABLUMINUS Below the Knee (BTK) Drug Eluting Stent (DES) Registry (ABLUMINUS BTK) - First in Men
Table 90: Abluminus DES+ - Randomized Trial Investigating Clinical Outcomes of Two Sirolimus-Eluting Stents in Diabetes Mellitus
Table 91: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 92: Corio Pimecrolimus-Eluting Stent - Product Status
Table 93: Corio Pimecrolimus-Eluting Stent - Product Description
Table 94: Cypher Elite - Product Status
Table 95: Cypher Elite - Product Description
Table 96: NEVO Sirolimus-Eluting Coronary Stent - Product Status
Table 97: NEVO Sirolimus-Eluting Coronary Stent - Product Description 5
Table 98: Next Generation Coronary Stent - Product Status 5
Table 99: Next Generation Coronary Stent - Product Description 5
Table 100: DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 101: Stellium Stent - Product Status
Table 102: Stellium Stent - Product Description
Table 103: Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 104: DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
Table 105: DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
Table 106: DynamX Drug Eluting Coronary Bioadaptor System - Product Status
Table 107: DynamX Drug Eluting Coronary Bioadaptor System - Product Description
Table 108: Myolimus Eluting Coronary Stent - Durable Polymer - Product Status
Table 109: Myolimus Eluting Coronary Stent - Durable Polymer - Product Description
Table 110: Elixir Medical Corp - Ongoing Clinical Trials Overview
Table 111: DynamX Drug Eluting Coronary Bioadaptor System - DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Novolimus Eluting Coronary Bioadaptor System (Bio-RESTORE)
Table 112: DynamX Drug Eluting Coronary Bioadaptor System - DYNAMX Bioadaptor Implantation for the Treatment of Complex Coronary Lesions (DYNAMITE Study)
Table 113: DynamX Drug Eluting Coronary Bioadaptor System - Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805
Table 114: DynamX Drug Eluting Coronary Bioadaptor System - Infinity-swedeheart Study: Registry Based Randomized Clinical Trial (R-RCT) Comparing Long Term Outcomes of the DynamX Bioadaptor to the Resolute Onyx Stent in a More-comer PCI Patient Population
Table 115: Endomimetics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 116: Coronary Artery Stent - Product Status
Table 117: Coronary Artery Stent - Product Description
Table 118: Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 119: Paclitaxel Eluting Stent - Product Status
Table 120: Paclitaxel Eluting Stent - Product Description
Table 121: I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview
Table 122: Drug Eluting Stent - Product Status(I.B.S. S.p.A.)
Table 123: Drug Eluting Stent - Product Description(I.B.S. S.p.A.)
Table 124: InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview 5
Table 125: MGuard Drug Eluting Stent - Product Status 5
Table 126: MGuard Drug Eluting Stent - Product Description 5
Table 127: JW Medical Systems Ltd Pipeline Products & Ongoing Clinical Trials Overview 6
Table 128: Excel II DES - Product Status 6
Table 129: Excel II DES - Product Description 6
Table 130: Kaneka Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 131: MAHOROBA Stent - Product Status
Table 132: MAHOROBA Stent - Product Description
Table 133: MangoGen Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 134: Gene-Delivering Stent - Product Status
Table 135: Gene-Delivering Stent - Product Description
Table 136: Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 137: IoNIR Ridaforolimus-Eluting Coronary Stent System - Product Status
Table 138: IoNIR Ridaforolimus-Eluting Coronary Stent System - Product Description
Table 139: Medinol Ltd - Ongoing Clinical Trials Overview
Table 140: IoNIR Ridaforolimus-Eluting Coronary Stent System - IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Table 141: IoNIR Ridaforolimus-Eluting Coronary Stent System - IonMAN Trial-First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
Table 142: Medlogics Device Corp (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 143: COBRA-Q Drug Eluting Stent - Product Status
Table 144: COBRA-Q Drug Eluting Stent - Product Description
Table 145: SYNERGY - Product Status
Table 146: SYNERGY - Product Description
Table 147: Medtronic Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 148: Drug Filled Stent - Product Status
Table 149: Drug Filled Stent - Product Description
Table 150: Resolute Onyx DES - DAPT - Product Status
Table 151: Resolute Onyx DES - DAPT - Product Description
Table 152: Medtronic Plc - Ongoing Clinical Trials Overview 5
Table 153: Resolute Onyx DES - DAPT - BIOTRONIK- A Prospective, Randomised, Multi-center Study to Assess the Safety of the Orsiro Mission Stent Compared to Resolute Onyx Stent in Subjects at High Risk of Bleeding in Combination With 1-month Dual Antiplatelet Therapy (DAPT) 5
Table 154: MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 6
Table 155: Fantasy Drug-Eluting Stent - Product Status 6
Table 156: Fantasy Drug-Eluting Stent - Product Description 6
Table 157: Firebird Pro+ - Product Status 7
Table 158: Firebird Pro+ - Product Description 7
Table 159: Firebird2 Pro - Product Status 7
Table 160: Firebird2 Pro - Product Description 7
Table 161: Firehawk Plus - Product Status
Table 162: Firehawk Plus - Product Description
Table 163: MicroPort Scientific Corp - Ongoing Clinical Trials Overview
Table 164: Firehawk Plus - LARGE-ONE: A Prospective, Multicenter, Randomized Controlled Trial of the Use of Drug-coating Balloons(DCB) or Drug-eluting Stents(DES) in the Treatment of Large Diameter Coronary Atherosclerotic Lesions
Table 165: MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 166: Smart-2 DES - Product Status
Table 167: Smart-2 DES - Product Description
Table 168: Smart-3 DES - Product Status
Table 169: Smart-3 DES - Product Description
Table 170: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
Table 171: Liquid Drug Eluting Stent - Product Status
Table 172: Liquid Drug Eluting Stent - Product Description
Table 173: NuVascular Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 174: NuSpun DE Stent Sheath - Product Status
Table 175: NuSpun DE Stent Sheath - Product Description
Table 176: Relisys Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 177: Corel + C Drug Eluting Stent - Product Status
Table 178: Corel + C Drug Eluting Stent - Product Description
Table 179: REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 5
Table 180: ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status 5
Table 181: ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description 5
Table 182: ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold - Product Status 6
Table 183: ReZolve2 Drug Eluting Bioresorbable Coronary Scaffold - Product Description 6
Table 184: Shandong Rientech Medical Tech Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 7
Table 185: Absorbable Zinc Alloy Drug Eluting Coronary Stent System - Product Status 7
Table 186: Absorbable Zinc Alloy Drug Eluting Coronary Stent System - Product Description 7
Table 187: Shandong Rientech Medical Tech Co Ltd - Ongoing Clinical Trials Overview 8
Table 188: Absorbable Zinc Alloy Drug Eluting Coronary Stent System - Exploratory Study on the Safety and Effectiveness of Absorbable Zinc Alloy Drug-eluting Coronary Stent System 8
Table 189: Shanghai BIOMAGIC Medical Device Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 190: BIOMAGIC Biroresorbable Coronary Stent - Product Status
Table 191: BIOMAGIC Biroresorbable Coronary Stent - Product Description
Table 192: Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 193: Firehawk Rapamycin Target Eluting Coronary Stent System - Product Status
Table 194: Firehawk Rapamycin Target Eluting Coronary Stent System - Product Description
Table 195: Shanghai MicroPort Medical Group Co Ltd - Ongoing Clinical Trials Overview
Table 196: Firehawk Rapamycin Target Eluting Coronary Stent System - A Prospective Multi-center Open-label Controlled Trial of Comparison 3 Versus 12 Months of Dual Anti-platelet Therapy after Implantation of Firehawk Sirolimus Target- eluting Stent in Patients with Stable Coronary Artery Disease
Table 197: Firehawk Rapamycin Target Eluting Coronary Stent System - A Prospective, Multicenter, Single-arm Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in Patients with Coronary Artery Stenosis
Table 198: Firehawk Rapamycin Target Eluting Coronary Stent System - A Prospective, Open Label, Multi-center Trial of Firehawk Coronary Stent System in the Treatment of Coronary Chronic Total Artery Occlusion Lesion(S) by Optical Coherent Tomography (OCT) and Coronary Angiography
Table 199: Firehawk Rapamycin Target Eluting Coronary Stent System - Assessment of In-stent Intimal Repair and Vessel Reaction After Firehawk Sirolimus Eluting Stent Implantation of STEMI Subjects - An Optical Coherence Tomography (OCT) Study
Table 200: Firehawk Rapamycin Target Eluting Coronary Stent System - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 201: Firehawk Rapamycin Target Eluting Coronary Stent System - LARGE-ONE: A Prospective, Multicenter, Randomized Controlled Trial of the Use of Drug-coating Balloons(DCB) or Drug-eluting Stents(DES) in the Treatment of Large Diameter Coronary Atherosclerotic Lesions
Table 202: Firehawk Rapamycin Target Eluting Coronary Stent System - Optical Coherence Tomography Compared with Intravascular Ultrasound or Quantitative Coronary Analysis to Guide Stent Implantation in the Treatment of Moderate-to-severe Calcified Lesion in Coronary Artery
Table 203: Sino Medical Sciences Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 5
Table 204: BuMA Supreme DES (Drug Eluting Stent) - Product Status 5
Table 205: BuMA Supreme DES (Drug Eluting Stent) - Product Description 6
Table 206: Supreme HT Drug-Eluting Stent - Product Status 6
Table 207: Supreme HT Drug-Eluting Stent - Product Description 6
Table 208: Sino Medical Sciences Technology Inc - Ongoing Clinical Trials Overview 7
Table 209: BuMA Supreme DES (Drug Eluting Stent) - A Prospective, Multicenter First-in-man Trial Program in China to Evaluate the Efficacy and Safety of Buma Supreme (Eg Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Subjects with De Novo Coronary Lesions, RCT Trial 8
Table 210: BuMA Supreme DES (Drug Eluting Stent) - A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients with de Novo Coronary Lesions, OPC Trial 8
Table 211: Supreme HT Drug-Eluting Stent - A Prospective, Multi-center, Single-group Target Value Post-marketing Clinical Study to Evaluate the Safety and Effectiveness of the HT Supreme Drug-eluting Stent System in the Treatment of Real-world Patients with Coronary Heart Disease 9
Table 212: Supreme HT Drug-Eluting Stent - Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated with Unrestricted Use of the Healing-targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy after 1-month of Dual-antiplatelet Therapy 9
Table 213: Stentys SA Pipeline Products & Ongoing Clinical Trials Overview 0
Table 214: STENTYS Paclitaxe

$4,000
$8,000
$12,000

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings